Current status of amantadine and rimantadine as anti-influenza-A agents: memorandum from a WHO meeting.
Identifieur interne : 001087 ( Ncbi/Merge ); précédent : 001086; suivant : 001088Current status of amantadine and rimantadine as anti-influenza-A agents: memorandum from a WHO meeting.
Auteurs :Source :
- Bulletin of the World Health Organization [ 0042-9686 ] ; 1985.
Descripteurs français
- KwdFr :
- MESH :
- analogues et dérivés : Adamantane.
- traitement médicamenteux : Grippe humaine.
- usage thérapeutique : Amantadine, Rimantadine.
- Humains, Virus de la grippe A.
English descriptors
- KwdEn :
- MESH :
- chemical , analogs & derivatives : Adamantane.
- chemical , therapeutic use : Amantadine, Rimantadine.
- drug therapy : Influenza, Human.
- Humans, Influenza A virus.
Abstract
Amantadine (1-adamantanamine hydrochloride), an anti-influenza drug, effectively inhibits the replication of all human subtypes of influenza A virus (H1N1, H2N2 and H3N2) both in laboratory studies and in a variety of clinical situations in young and old persons. So far, it has been used on a relatively limited scale by community and hospital clinicians, partly because of concern over mild side-effects in approximately 6% of persons. The related compound, rimantadine (alpha-methyl-1-adamantane-methylamine hydrochloride), shows comparable antiviral activity with few or no side-effects. Although the mode of antiviral action is considered to be similar, the two drugs differ in their metabolic and pharmacological properties.Both amantadine and rimantadine have therapeutic uses and shorten the duration of influenza-A-induced fever, malaise, and virus shedding. A dosage of 200 mg of either drug for a 3-5-day period is effective but treatment has to commence on the first day of symptoms. Prophylaxis, particularly using rimantadine, could be usefully initiated in elderly and other high-risk individuals living in institutions and in the general community.
PubMed: 3872736
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000512
- to stream PubMed, to step Curation: 000512
- to stream PubMed, to step Checkpoint: 000448
Links to Exploration step
pubmed:3872736Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Current status of amantadine and rimantadine as anti-influenza-A agents: memorandum from a WHO meeting.</title></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1985">1985</date><idno type="RBID">pubmed:3872736</idno><idno type="pmid">3872736</idno><idno type="wicri:Area/PubMed/Corpus">000512</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000512</idno><idno type="wicri:Area/PubMed/Curation">000512</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000512</idno><idno type="wicri:Area/PubMed/Checkpoint">000448</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000448</idno><idno type="wicri:Area/Ncbi/Merge">001087</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Current status of amantadine and rimantadine as anti-influenza-A agents: memorandum from a WHO meeting.</title></analytic><series><title level="j">Bulletin of the World Health Organization</title><idno type="ISSN">0042-9686</idno><imprint><date when="1985" type="published">1985</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adamantane (analogs & derivatives)</term><term>Amantadine (therapeutic use)</term><term>Humans</term><term>Influenza A virus</term><term>Influenza, Human (drug therapy)</term><term>Rimantadine (therapeutic use)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adamantane (analogues et dérivés)</term><term>Amantadine (usage thérapeutique)</term><term>Grippe humaine (traitement médicamenteux)</term><term>Humains</term><term>Rimantadine (usage thérapeutique)</term><term>Virus de la grippe A</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Adamantane</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Amantadine</term><term>Rimantadine</term></keywords><keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>Adamantane</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Amantadine</term><term>Rimantadine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Influenza A virus</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Humains</term><term>Virus de la grippe A</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Amantadine (1-adamantanamine hydrochloride), an anti-influenza drug, effectively inhibits the replication of all human subtypes of influenza A virus (H1N1, H2N2 and H3N2) both in laboratory studies and in a variety of clinical situations in young and old persons. So far, it has been used on a relatively limited scale by community and hospital clinicians, partly because of concern over mild side-effects in approximately 6% of persons. The related compound, rimantadine (alpha-methyl-1-adamantane-methylamine hydrochloride), shows comparable antiviral activity with few or no side-effects. Although the mode of antiviral action is considered to be similar, the two drugs differ in their metabolic and pharmacological properties.Both amantadine and rimantadine have therapeutic uses and shorten the duration of influenza-A-induced fever, malaise, and virus shedding. A dosage of 200 mg of either drug for a 3-5-day period is effective but treatment has to commence on the first day of symptoms. Prophylaxis, particularly using rimantadine, could be usefully initiated in elderly and other high-risk individuals living in institutions and in the general community.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">3872736</PMID><DateCompleted><Year>1985</Year><Month>06</Month><Day>07</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0042-9686</ISSN><JournalIssue CitedMedium="Print"><Volume>63</Volume><Issue>1</Issue><PubDate><Year>1985</Year></PubDate></JournalIssue><Title>Bulletin of the World Health Organization</Title><ISOAbbreviation>Bull. World Health Organ.</ISOAbbreviation></Journal><ArticleTitle>Current status of amantadine and rimantadine as anti-influenza-A agents: memorandum from a WHO meeting.</ArticleTitle><Pagination><MedlinePgn>51-6</MedlinePgn></Pagination><Abstract><AbstractText>Amantadine (1-adamantanamine hydrochloride), an anti-influenza drug, effectively inhibits the replication of all human subtypes of influenza A virus (H1N1, H2N2 and H3N2) both in laboratory studies and in a variety of clinical situations in young and old persons. So far, it has been used on a relatively limited scale by community and hospital clinicians, partly because of concern over mild side-effects in approximately 6% of persons. The related compound, rimantadine (alpha-methyl-1-adamantane-methylamine hydrochloride), shows comparable antiviral activity with few or no side-effects. Although the mode of antiviral action is considered to be similar, the two drugs differ in their metabolic and pharmacological properties.Both amantadine and rimantadine have therapeutic uses and shorten the duration of influenza-A-induced fever, malaise, and virus shedding. A dosage of 200 mg of either drug for a 3-5-day period is effective but treatment has to commence on the first day of symptoms. Prophylaxis, particularly using rimantadine, could be usefully initiated in elderly and other high-risk individuals living in institutions and in the general community.</AbstractText></Abstract><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Bull World Health Organ</MedlineTA><NlmUniqueID>7507052</NlmUniqueID><ISSNLinking>0042-9686</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0T2EF4JQTU</RegistryNumber><NameOfSubstance UI="D012299">Rimantadine</NameOfSubstance></Chemical><Chemical><RegistryNumber>BF4C9Z1J53</RegistryNumber><NameOfSubstance UI="D000547">Amantadine</NameOfSubstance></Chemical><Chemical><RegistryNumber>PJY633525U</RegistryNumber><NameOfSubstance UI="D000218">Adamantane</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000218" MajorTopicYN="N">Adamantane</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs & derivatives</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000547" MajorTopicYN="N">Amantadine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009980" MajorTopicYN="N">Influenza A virus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012299" MajorTopicYN="N">Rimantadine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1985</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1985</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1985</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">3872736</ArticleId><ArticleId IdType="pmc">PMC2536349</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Br J Exp Pathol. 1965 Aug;46(4):370-5</Citation><ArticleIdList><ArticleId IdType="pubmed">5317962</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Exp Pathol. 1965 Jun;46(3):263-73</Citation><ArticleIdList><ArticleId IdType="pubmed">4284028</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pharmacol Exp Ther. 1965 Dec;150(3):484-90</Citation><ArticleIdList><ArticleId IdType="pubmed">4954953</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 1968 Mar 25;203(13):1089-94</Citation><ArticleIdList><ArticleId IdType="pubmed">4868123</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 1969 Nov 15;2(7629):1026-8</Citation><ArticleIdList><ArticleId IdType="pubmed">4187541</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 1970 Feb 16;211(7):1149-56</Citation><ArticleIdList><ArticleId IdType="pubmed">4904254</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1970 Apr 4;226(5240):82-3</Citation><ArticleIdList><ArticleId IdType="pubmed">5434369</ArticleId></ArticleIdList></Reference><Reference><Citation>Bull World Health Organ. 1969;41(3):677-82</Citation><ArticleIdList><ArticleId IdType="pubmed">4908342</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 1972 Nov 13;222(7):792-5</Citation><ArticleIdList><ArticleId IdType="pubmed">4677928</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Epidemiol. 1973 Apr;97(4):276-82</Citation><ArticleIdList><ArticleId IdType="pubmed">4697648</ArticleId></ArticleIdList></Reference><Reference><Citation>Antimicrob Agents Chemother. 1972 May;1(5):408-11</Citation><ArticleIdList><ArticleId IdType="pubmed">4670482</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 1978 Feb;3(2):119-28</Citation><ArticleIdList><ArticleId IdType="pubmed">350129</ArticleId></ArticleIdList></Reference><Reference><Citation>Am Rev Respir Dis. 1978 Aug;118(2):295-303</Citation><ArticleIdList><ArticleId IdType="pubmed">358877</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 1978 Dec;28(3):710-6</Citation><ArticleIdList><ArticleId IdType="pubmed">731792</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 1979 Mar 9;241(10):1003-7</Citation><ArticleIdList><ArticleId IdType="pubmed">368354</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gen Virol. 1979 Sep;44(3):807-15</Citation><ArticleIdList><ArticleId IdType="pubmed">528983</ArticleId></ArticleIdList></Reference><Reference><Citation>Nurs Focus. 1980 Mar;1(7):278-80</Citation><ArticleIdList><ArticleId IdType="pubmed">6898996</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 1980 Apr 12;1(8172):793-5</Citation><ArticleIdList><ArticleId IdType="pubmed">6102679</ArticleId></ArticleIdList></Reference><Reference><Citation>Antimicrob Agents Chemother. 1980 May;17(5):865-70</Citation><ArticleIdList><ArticleId IdType="pubmed">7396473</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacol Ther. 1980;11(1):181-262</Citation><ArticleIdList><ArticleId IdType="pubmed">6159656</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Virol. 1980;66(3):275-82</Citation><ArticleIdList><ArticleId IdType="pubmed">7447705</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Epidemiol. 1981 Jan;113(1):30-43</Citation><ArticleIdList><ArticleId IdType="pubmed">7457477</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 1981 Mar 20;245(11):1128-31</Citation><ArticleIdList><ArticleId IdType="pubmed">7007668</ArticleId></ArticleIdList></Reference><Reference><Citation>Am Sci. 1981 Mar-Apr;69(2):166-72</Citation><ArticleIdList><ArticleId IdType="pubmed">7224331</ArticleId></ArticleIdList></Reference><Reference><Citation>Rev Infect Dis. 1981 May-Jun;3(3):408-21</Citation><ArticleIdList><ArticleId IdType="pubmed">7025146</ArticleId></ArticleIdList></Reference><Reference><Citation>Bull World Health Organ. 1981;59(3):305-24</Citation><ArticleIdList><ArticleId IdType="pubmed">6976841</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 1982 Mar 12;247(10):1451-3</Citation><ArticleIdList><ArticleId IdType="pubmed">7057536</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Virol. 1981 Nov;25(6):395-400</Citation><ArticleIdList><ArticleId IdType="pubmed">6120642</ArticleId></ArticleIdList></Reference><Reference><Citation>MMWR Morb Mortal Wkly Rep. 1982 Apr 23;31(15):190, 195</Citation><ArticleIdList><ArticleId IdType="pubmed">6808335</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 1982 Sep 2;307(10):580-4</Citation><ArticleIdList><ArticleId IdType="pubmed">7050702</ArticleId></ArticleIdList></Reference><Reference><Citation>Antimicrob Agents Chemother. 1983 Mar;23(3):458-64</Citation><ArticleIdList><ArticleId IdType="pubmed">6847173</ArticleId></ArticleIdList></Reference><Reference><Citation>Antimicrob Agents Chemother. 1983 Apr;23(4):577-82</Citation><ArticleIdList><ArticleId IdType="pubmed">6859836</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 1984 Mar 3;1(8375):502-4</Citation><ArticleIdList><ArticleId IdType="pubmed">6142218</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1964 May 15;144(3620):862-3</Citation><ArticleIdList><ArticleId IdType="pubmed">14151624</ArticleId></ArticleIdList></Reference><Reference><Citation>Antimicrob Agents Chemother (Bethesda). 1963;161:703-7</Citation><ArticleIdList><ArticleId IdType="pubmed">14274988</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 1965 Jun;26:262-9</Citation><ArticleIdList><ArticleId IdType="pubmed">14323994</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list></list><tree></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001087 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 001087 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= H2N2V1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:3872736
|texte= Current status of amantadine and rimantadine as anti-influenza-A agents: memorandum from a WHO meeting.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:3872736" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a H2N2V1
| This area was generated with Dilib version V0.6.33. |  |